Release Time：2025-04-02 13:58:14Source：Eyebright
On March 22, the 2025 Future Science City Science and Technology Innovation Finance Conference was held under the theme "Gathering Financial 'Vitality' to Co-create a New Quality Future." The conference was jointly organized by the Changping District Government of Beijing, the Management Committee of Future Science City, and Beijing State-owned Capital Operation Management Co., Ltd.
Notable attendees included Hu Xiaolian, Vice Chairman of the China Center for International Economic Exchanges and former Deputy Governor of the People's Bank of China; Xie Ping, former Vice General Manager of China Investment Corporation and former Director of the Research Bureau of the People's Bank of China; Ding Zhangchun, Deputy Secretary-General of the Beijing Municipal People's Government; Wu Yunhao, Secretary of the Party Committee of the Beijing Regulatory Bureau of the China Securities Regulatory Commission; and other leaders from Beijing and Changping District. Dr. Xie Jiangbing, representing Eyebright Medical, participated in the launch ceremony of the technology industry fund cluster and theme dialogue.
During the conference, experts, scholars from the financial sector, government officials, relevant institutions, and representatives of technology enterprises based in Changping gathered to discuss trends in science and technology finance and the future of "government-business-bank" collaboration, aiming to jointly build a demonstration zone for capital city science and technology finance and support the construction of Beijing as an international science and technology innovation center.
Dr. Xie emphasized that capital has played an irreplaceable role in Eyebright Medical's growth trajectory. From multiple rounds of venture capital investment during its startup phase to a successful IPO and subsequent refinancing, the company has maintained close cooperation with its shareholders. This strong partnership is significant, enhancing the company's core competitiveness in a complex and ever-changing market environment. Continuous capital infusion from shareholders provides solid financial support for Eyebright Medical's technological research and development, market expansion, and talent cultivation, propelling the company forward steadily.
Following its successful IPO, Eyebright Medical actively focuses on its core industries and expands through initiating or participating in various funds for external growth. This approach allows for rapid scale expansion by leveraging external resources, broadening business boundaries, and capturing new market shares and profit growth points. Additionally, by integrating upstream and downstream resources in the industry chain, the company achieves synergistic effects, strengthening its market position and helping it stand out in fierce competition for sustainable development. Dr. Xie also shared unique insights on the impact of AI on the industry.
The deep integration of finance and technological innovation has provided strong support for Eyebright Medical's high-quality development. Moving forward, the company will continue to focus on hard technology breakthroughs, precisely channeling capital into core technology research and development, and deepening the collaborative development of the industry chain, innovation chain, and capital chain—empowering technological innovation through finance and driving industrial development through innovation.
